Literature DB >> 12000992

Inhibition of 50S ribosomal subunit assembly in Haemophilus influenzae cells by azithromycin and erythromycin.

W Scott Champney1, Mindy Miller.   

Abstract

Azithromycin is an important antibiotic for the treatment of several different Gram-positive and Gram-negative bacterial infections. Erythromycin and clarithromycin are less useful antibiotics against Gram-negative infections. This difference in inhibitory activity was explored by comparing the effects of azithromycin and erythromycin on cellular functions in Haemophilus influenzae cells. Effects of both antibiotics on translation, cell viability, and growth rates have been measured. An IC(50) of 0.4 microg/ml was found for the effects of azithromycin on each of these processes. For erythromycin, an IC(50) of 1.5 microg/ml was observed, indicating a fourfold lower sensitivity of the organisms to this compound. The features of a second target for macrolide antibiotic inhibition in H. influenzae cells have also been examined. Inhibition of the synthesis of the large 50S ribosomal subunit was measured. Subunit formation was prevented in a concentration dependent fashion, with azithromycin showing a ninefold greater effect on this process compared with erythromycin. Synthesis of the 30S ribosomal subunit was not effected. Pulse and chase labeling kinetics confirmed the slower synthesis rate of the 50S particle in the presence of each antibiotic. The results are discussed in terms of the stronger effect of azithromycin on ribosome biosynthesis in this organism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12000992     DOI: 10.1007/s00284-001-0016-6

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  11 in total

Review 1.  Inhibition of bacterial ribosome assembly: a suitable drug target?

Authors:  Bruce A Maguire
Journal:  Microbiol Mol Biol Rev       Date:  2009-03       Impact factor: 11.056

Review 2.  The macrolide antibiotic renaissance.

Authors:  George P Dinos
Journal:  Br J Pharmacol       Date:  2017-08-10       Impact factor: 8.739

3.  Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa.

Authors:  Thilo Köhler; Jean-Luc Dumas; Christian Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

4.  Erythromycin- and chloramphenicol-induced ribosomal assembly defects are secondary effects of protein synthesis inhibition.

Authors:  Triinu Siibak; Lauri Peil; Liqun Xiong; Alexander Mankin; Jaanus Remme; Tanel Tenson
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

5.  Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy.

Authors:  Mitchell H Friedlaender; Eugene Protzko
Journal:  Clin Ophthalmol       Date:  2007-03

Review 6.  A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.

Authors:  Parastoo Tarighi; Samane Eftekhari; Milad Chizari; Mahsa Sabernavaei; Davod Jafari; Parastoo Mirzabeigi
Journal:  Eur J Pharmacol       Date:  2021-01-20       Impact factor: 5.195

7.  Effects of Four Types of Watermelon Frost Combination Medications for the Treatment of Oral Ulcers: A Network Meta-Analysis.

Authors:  Zhenhua Liu; Huiqin Dou
Journal:  J Healthc Eng       Date:  2022-03-12       Impact factor: 2.682

8.  Evidence of Horizontal Gene Transfer of 50S Ribosomal Genes rplB, rplD, and rplY in Neisseria gonorrhoeae.

Authors:  Sheeba Santhini Manoharan-Basil; Jolein Gyonne Elise Laumen; Christophe Van Dijck; Tessa De Block; Irith De Baetselier; Chris Kenyon
Journal:  Front Microbiol       Date:  2021-06-10       Impact factor: 5.640

9.  Screening paediatric rectal forms of azithromycin as an alternative to oral or injectable treatment.

Authors:  Tina Kauss; Karen Gaudin; Alexandra Gaubert; Boubakar Ba; Serena Tagliaferri; Fawaz Fawaz; Jean-Louis Fabre; Jean-Michel Boiron; Xavier Lafarge; Nicholas J White; Piero L Olliaro; Pascal Millet
Journal:  Int J Pharm       Date:  2012-07-30       Impact factor: 5.875

10.  Relative effectiveness of azithromycin in killing intracellular Porphyromonas gingivalis.

Authors:  Pin-Chuang Lai; John D Walters
Journal:  Clin Exp Dent Res       Date:  2016-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.